Cowen and Company’s Adverum Biotechnologies ADVM Stock Holding History

Cowen and Company’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-3,000	Closed	-$2K	–	450
2019 Q3	$2K	Buy	+3,000	New	+$338K	﹤0.01%	434

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cowen and Company's ADVM Position: Q1 2022 in Review

Cowen and Company sold out of Adverum Biotechnologies (ADVM) in Q1 2022, closing a stake of 97,218 shares — an estimated $1.71M sold.

Cowen and Company first reported a position in ADVM in Q4 2019 and held it in 5 quarters. The position peaked at $3.35M in Q2 2020. 92 funds tracked by Wall St. Rank hold ADVM as of Q1 2022.

Cowen and Company reported no remaining Adverum Biotechnologies position as of Q1 2022 after selling out during the quarter.
Cowen and Company sold 97,218 Adverum Biotechnologies shares in Q1 2022, an estimated $1.71M.
Cowen and Company first reported a position in Adverum Biotechnologies in Q4 2019 and held it in 5 quarters.
Cowen and Company's Adverum Biotechnologies position peaked at $3.35M in Q2 2020.
92 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2022.

Based on Cowen and Company's 13F filing for Q1 2022, filed 16 May 2022.